Cardiometabolic Task Force
The Momentum Cardiometabolic Taskforce brings together specialist investigators and operational leaders across Australia and New Zealand to strengthen the planning and delivery of obesity, diabetes, metabolic and cardiovascular clinical trials.
Led by Dr King Cheung MD, the taskforce gives sponsors direct access to experienced clinicians from protocol design onwards, with early consultation available to support clinical development planning. Our investigators and clinical operations specialists contribute to sponsor calls, feasibility reviews and bid defenses, bringing practical insight into participant eligibility, recruitment and study delivery from the people who will conduct your trial.

Cardoiometabolic Taskforce: Alyce King- Commercial Lead; Dr Milan Radojevic - Principal Investigator; Nina Linton RN - Research Area Manager; Dr Rakesh Iyer FRACP - Endocrinologist and Dr King Cheung MD - Principal Investigator and taskforce lead.

Dr King Cheung MD - Taskforce Lead
Prinicpal Investigator: 132 clinical studies, including 32 cardiometabolic and 24 obesity and incretin trials.
We've established this taskforce to give clinical trial sponsors direct access to specialist expertise from the very beginning of their research programmes.
Our team brings together experienced investigators and operational leaders from across Australia and New Zealand, specialising in obesity, diabetes, metabolic and cardiovascular research.
What makes our approach different is that we're directly involved in sponsor discussions, feasibility assessments and recruitment planning from day one.
This means we can provide practical clinical insight, help identify potential challenges early and develop realistic recruitment strategies, giving sponsors greater confidence in study delivery.
And because we're part of Momentum's connected Australasian network, we can bring together purpose-built cardiometabolic research centres, specialist investigators and diverse participant populations, with coordinated recruitment across both countries.
For sponsors, that means earlier access to expertise, broader recruitment reach and a simpler, more connected approach to clinical trial delivery.
If you're planning a cardiometabolic study, we'd welcome the opportunity to discuss your programme and how our taskforce can support you.
Get in touch with our team or request an information brochure using the contact form on this page.

Our experience in numbers
Momentum cardiometabolic trials, delivered at scale
Participants screened in 5 years
Participants randomised
+
Sites awarded across 50+ cardiometabolic studies
Cardiometabolic specialists

Why Australia and New Zealand?
Australia and New Zealand combine diverse participant populations, a substantial cardiometabolic disease burden and established clinical trial infrastructure.
Significant disease burden. Over 30% of Australian and New Zealand adults live with obesity. These populations highlight the need for further research across obesity, type 2 diabetes and associated cardiovascular conditions.
Gaps in access to newer therapies. GLP-1 and dual GIP/GLP-1 medicines for weight management are not publicly funded in either country, meaning patients generally pay privately. This can create opportunities to recruit participants who have not previously received these therapies, subject to study eligibility criteria.
Complementary recruitment environments. Australia provides population scale and major metropolitan hubs, while New Zealand extends recruitment reach into diverse communities. Together, they offer sponsors complementary settings for cardiometabolic research.
Established regulatory pathways support efficient study start-up, with internationally recognised clinical research capabilities and Australia’s R&D Tax Incentive providing additional advantages for sponsors.
Why Momentum?
Specialist expertise. Connected capability. One fully integrated network delivering your study.
Momentum brings together purpose-built cardiometabolic sites, experienced investigators and centralised recruitment across Australia and New Zealand to support obesity, diabetes and cardiovascular research from Phase I–IV.
Our Cardiometabolic Taskforce gives sponsors direct access to specialist investigators and operational leaders from the earliest stages of study planning. Their insight strengthens feasibility, informs recruitment strategies and helps align each study with the right clinical capabilities and participant populations.
With one coordinated team and a single point of contact, sponsors can access the expertise and reach of our entire network, supported by centralised feasibility, contracting and study management.

Why Momentum?

Specialist expertise. Connected capability. One fully integrated network delivering your study.
Momentum brings together purpose-built cardiometabolic sites, experienced investigators and centralised recruitment across Australia and New Zealand to support obesity, diabetes and cardiovascular research from Phase I–IV.
Our Cardiometabolic Taskforce gives sponsors direct access to specialist investigators and operational leaders from the earliest stages of study planning. Their insight strengthens feasibility, informs recruitment strategies and helps align each study with the right clinical capabilities and participant populations.
With one coordinated team and a single point of contact, sponsors can access the expertise and reach of our entire network, supported by centralised feasibility, contracting and study management.
Cardiometabolic capabilities
Partner with Momentum
If you are interested in exploring how Momentum can assist with your next clinical trial, then please reach out to us here.
Our taskforce joins sponsor calls, feasibility reviews and bid defences, so you hear directly from the investigators who will deliver your study.